Kontigo Care AB (KONT) AI Stock Analysis

• Market Cap: kr72.62M
• Dividend Yield: N/A
• Average Volume (3M): 44.12K
• Price to Earnings (P/E): 316.7
• Beta (1Y): 0.02
• Revenue Growth: 0.84%
• EPS Growth: -79.94%
• Country: SE
• Employees: 12
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.02
• Shares Outstanding: 35,251,427
• 10 Day Avg. Volume: 22,601
• 30 Day Avg. Volume: 44,123
• PEG Ratio: -8.34
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -20.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr2.01
• Price Target Upside: -4.20% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: kr2.00 ▼(-4.76%Downside)

The overall stock score for Kontigo Care AB is driven by its stable financial position with strong equity and low leverage. However, the high P/E ratio suggests overvaluation, and technical indicators point to a bearish trend. Improvement in revenue growth and liquidity management could enhance the company's financial performance.

Kontigo Care AB Business Overview & Revenue Model

Company Description

Kontigo Care AB (KONT) is a Swedish company operating in the healthcare technology sector. The company specializes in developing digital solutions aimed at improving the treatment and rehabilitation processes for individuals with addiction issues. Its flagship product, Previct, is an eHealth platform that combines mobile technology, data analytics, and artificial intelligence to offer real-time monitoring and support for patients undergoing addiction treatment.

How the Company Makes Money

Kontigo Care AB generates revenue primarily through the sale and licensing of its digital health platform, Previct, to healthcare providers and institutions. The company offers its solutions on a subscription basis, which includes access to the platform, continuous updates, and customer support. Additionally, Kontigo Care collaborates with healthcare organizations and partners to further integrate its technology into existing treatment programs, enhancing its market reach and revenue potential. Significant factors contributing to its earnings include the increasing demand for innovative addiction treatment solutions and the growing adoption of digital health technologies in the healthcare industry.

Kontigo Care AB Financial Statement Overview

Summary

Kontigo Care AB exhibits a stable financial position with a strong balance sheet characterized by low leverage and high equity. While the company shows operational profitability, the income statement and cash flow metrics suggest areas for improvement in revenue growth and liquidity management.

Income Statement

Kontigo Care AB has demonstrated reasonable growth and stability in its income statement with a recent TTM revenue of 29.7M and improved metrics such as a gross profit margin of 100.45% and a net profit margin of 0.39%. However, the revenue growth rate has seen a slight decline of -1.73% from the previous annual period. The EBIT and EBITDA margins show healthy positions at 0.38% and 16.23% respectively, indicating profitable operations despite fluctuations in revenue growth.

Balance Sheet

The balance sheet of Kontigo Care AB reflects a strong equity position with an equity ratio of 80.47%. The debt-to-equity ratio is low at 0.06, suggesting low leverage and reduced financial risk. Return on equity stands at 0.23%, which is modest and showcases room for improvement in profitability from existing equity.

Cash Flow

The cash flow statement indicates challenges with negative free cash flow of -3.62M in the TTM period, reflecting potential liquidity constraints. However, the operating cash flow to net income ratio is robust at 30.64, indicating efficient cash generation from operations relative to net income. Free cash flow to net income ratio remains negative, highlighting concerns in covering capital expenditures from generated profits.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.24M	28.95M	28.43M	24.54M	20.38M
Gross Profit	40.08M	43.73M	28.24M	24.16M	20.01M
EBITDA	5.07M	1.79M	4.13M	2.67M	2.20M
Net Income	775.00K	212.00K	2.90M	-1.20M	-1.28M
Balance Sheet
Total Assets	67.74M	49.77M	31.39M	29.20M	24.46M
Cash, Cash Equivalents and Short-Term Investments	21.86M	9.85M	5.74M	8.48M	4.94M
Total Debt	3.67M	5.95M	0.00	1.08K	539.82K
Total Liabilities	15.42M	19.05M	9.98M	10.74M	9.07M
Stockholders Equity	52.32M	30.72M	21.40M	18.46M	15.40M
Cash Flow
Free Cash Flow	-5.61M	-9.07M	-2.20M	272.26K	248.43K
Operating Cash Flow	4.61M	5.97M	7.30M	4.61M	3.99M
Investing Cash Flow	-10.70M	-16.73M	-9.50M	-4.34M	-3.74M
Financing Cash Flow	18.11M	14.87M	-540.00K	3.27M	-987.76K

Kontigo Care AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KONT, the sentiment is Negative. The current price of 2.1 is above the 20-day moving average (MA) of 2.05, below the 50-day MA of 2.13, and below the 200-day MA of 2.46, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.10 is Neutral, neither overbought nor oversold. The STOCH value of 22.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:KONT.

Kontigo Care AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KONT	56 Neutral	kr72.62M	316.67	0.25%	―	0.84%	-79.94%
Sector *	52 Neutral	kr5.65B	11.48	-62.48%	1.93%	25.53%	21.64%
PILA	40 Underperform	kr124.35M	―		―	―	―
BIOSGN	34 Underperform	€126.33M	―	-56.71%	―	―	35.61%
ACTI	32 Underperform	kr255.26M	―	-186.40%	―	―	24.47%
AINO	29 Underperform	kr40.91M	―		―	0.10%	41.59%